Symbol | Exchange | Currency |
|---|
Dec 9 (Reuters) - Prescient Therapeutics Ltd PTX.AX :* PTX EXTENDS COVID-19 TESTING PROGRAM WITH DOHERTY INSTITUTE-PTX.AX* TO EXTEND TESTING PROGRAM FOR SARS-COV-2 ANTIVIRAL...
Aug 26 (Reuters) - Prescient Therapeutics Ltd PTX.AX :* RAISES $7 MILLION AT $0.055 PER SHARE
Aug 14 (Reuters) - Prescient Therapeutics Ltd PTX.AX :* ANNOUNCES RESEARCH COLLABORATION WITH PETER MACCALLUM CANCER CENTRE* COLLABORATION TO DEVELOP NEW CELL THERAPY...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Sell | Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Neutral | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 16.29 | 16.29 | 15.80 | +0.41 | +2.58% | 1.22M | Sydney | |||
| 26.49 | 26.81 | 26.48 | +0.080 | +0.30% | 2.37M | Sydney | |||
| 0.46 | 0.00 | 0.00 | -0.025 | -5.15% | 2.67M | Sydney | |||
| 2.05 | 2.06 | 2.04 | -0.010 | -0.49% | 644.07K | Sydney | |||
| 3.56 | 3.60 | 3.51 | -0.01 | -0.28% | 82.08K | Sydney | |||
| 0.30 | 0.00 | 0.00 | -0.020 | -6.25% | 5.74M | Sydney | |||
| 24.52 | 24.66 | 24.51 | 0.000 | 0.00% | 4.51M | Sydney | |||
| 53.49 | 54.55 | 53.29 | +0.160 | +0.30% | 7.13M | Sydney | |||
| 6.45 | 6.535 | 6.43 | -0.070 | -1.07% | 8.40M | Sydney | |||
| 96.66 | 101.47 | 96.66 | -5.39 | -5.28% | 1.29M | Sydney | |||
| 4.15 | 4.21 | 4.08 | -0.040 | -0.95% | 1.34M | Sydney | |||
| 24.91 | 26.49 | 24.895 | -1.390 | -5.29% | 13.18M | Sydney | |||
| 5.01 | 5.05 | 4.92 | +0.04 | +0.80% | 2.47M | Sydney | |||
| 6.64 | 6.90 | 6.63 | -0.30 | -4.32% | 7.68M | Sydney | |||
| 3.24 | 3.31 | 3.21 | -0.08 | -2.41% | 2.52M | Sydney |
Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The Company is engaged in developing compounds to treat a range of solid and hematological cancers. It is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.
